
CLAIMS

1. Use of a compound of formula I:



I

or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for the treatment of cancer, wherein the medicament is to be administered to a subject in a three-week cycle; wherein the medicament is to be administered as a single dose during the three-week cycle; and wherein the single dose is about 4.5 mg/m^2.

2. The use according to claim 1, wherein the single dose is 4.5 mg/m^2.

3. The use according to any preceding claim, wherein the medicament is to be administered as a single dose on Day 1 of the three-week cycle.

4. The use according to any preceding claim, wherein the medicament is to be administered parentally.

5. The use according to claim 4, wherein the medicament is to be administered intravenously.

6. The use according to claim 5, wherein the medicament is to be administered by infusion.

7. The use according to claim 6, wherein the infusion time is up to 24 hours.

8. The use according to claim 6, wherein the infusion time is 3 hours.


9. The use according to claim 6, wherein the infusion time is 24 hours.

10. The use according to claim 1, wherein the medicament is to be administered intravenously on Day 1 once every three weeks at a dose of 4.5 mg/m^2, with an infusion time of three hours.

11. The use according to any preceding claim, wherein the medicament is to be administered together with radiation therapy; said radiation therapy being administered prior to, concurrently with or subsequently to administration of the medicament.

12. The use according to any preceding claim, wherein the cancer is selected from melanoma, lung cancer including non-small cell lung cancer and small cell lung cancer, colon cancer, rectal cancer, colorectal cancer, breast cancer, pancreas cancer, sarcoma including soft tissue sarcoma or bone sarcoma, ovarian cancer, prostate cancer, gastric cancer, renal cancer, neuroendocrine tumor, endometrial cancer, adenoid cystic carcinoma and adrenocortical carcinoma.

13. Use of a compound of formula I:



I

or a pharmaceutically acceptable salt or ester thereof, in the manufacture of a medicament for the treatment of cancer, wherein the cancer is selected from melanoma, renal cancer, neuroendocrine tumor, endometrial cancer, adenoid cystic carcinoma, adrenocortical carcinoma, bone sarcoma and soft tissue sarcoma.

14. The use according to claim 12 or claim 13, wherein the cancer is renal cancer and the renal cancer is renal carcinoma, kidney clear cell carcinoma or hypernephroma.

15. The use according to claim 14, wherein the hypernephroma is poorly differentiated hypernephroma.

16. The use according to claim 12 or claim 13, wherein the cancer is melanoma.

17. The use according to claim 16, wherein the melanoma is amelanotic melanoma.

18. The use according to claim 12, wherein the cancer is soft tissue sarcoma and the soft tissue sarcoma is fibrosarcoma.

19. The use according to claim 12 or 13, wherein the cancer is soft tissue sarcoma and the soft tissue sarcoma is leiomyosarcoma.

20. The use according to claim 12 or claim 13, wherein the cancer is soft tissue sarcoma and the soft tissue sarcoma is liposarcoma.

21. The use according to claim 12 or 13, wherein the cancer is bone sarcoma and the bone sarcoma is chondrosarcoma.

22. The use according to claim 21 wherein the bone sarcoma is myxoid chondrosarcoma.

23. The use according to any preceding claim, wherein the salt is selected from hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate, p-toluenesulfonate, sodium, potassium, calcium, ammonium, ethylenediamine, ethanolamine, N,N-dialkylenethanolamine, triethanolamine and basic amino acids.